{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T13:51:00Z","timestamp":1786456260949,"version":"build-2736575974"},"reference-count":92,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the American Academy of Child & Adolescent Psychiatry"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.jaac.2013.11.005","type":"journal-article","created":{"date-parts":[[2013,11,25]],"date-time":"2013-11-25T22:31:27Z","timestamp":1385418687000},"page":"174-187","source":"Crossref","is-referenced-by-count":144,"title":["Efficacy and Safety of Atomoxetine in Children and Adolescents With Attention-Deficit\/Hyperactivity Disorder: Results From a Comprehensive Meta-Analysis and Metaregression"],"prefix":"10.1016","volume":"53","author":[{"given":"Shimon","family":"Schwartz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph U.","family":"Correll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaac.2013.11.005_bib1","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1176\/appi.ajp.164.6.942","article-title":"The worldwide prevalence of ADHD: a systematic review and metaregression analysis","volume":"164","author":"Polanczyk","year":"2007","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jaac.2013.11.005_bib2","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/00004583-200105000-00009","article-title":"Preschool children with attention-deficit\/hyperactivity disorder: impairments in\u00a0behavioral, social, and school functioning","volume":"40","author":"DuPaul","year":"2001","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2013.11.005_bib3","doi-asserted-by":"crossref","first-page":"i2","DOI":"10.1136\/adc.2004.059006","article-title":"The effect of ADHD on the life of an individual, their family, and community from preschool to adult life","volume":"90","author":"Harpin","year":"2005","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.jaac.2013.11.005_bib4","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/00004583-200102000-00009","article-title":"ADHD comorbidity findings from the MTA study: comparing comorbid subgroups","volume":"40","author":"Jensen","year":"2001","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2013.11.005_bib5","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0893-133X(02)00346-9","article-title":"Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention-deficit\/ hyperactivity disorder","volume":"27","author":"Bymaster","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jaac.2013.11.005_bib6","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1542\/peds.2011-2654","volume":"128","author":"Wolraich","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaac.2013.11.005_bib7","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1753-2000-2-25","article-title":"Acute atomoxetine treatment of younger and older children with ADHD: a meta-analysis of tolerability and efficacy","volume":"2","author":"Kratochvil","year":"2008","journal-title":"Child Adolesc Psychiatry Ment Health"},{"key":"10.1016\/j.jaac.2013.11.005_bib8","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1753-2000-4-30","article-title":"Differences between children and adolescents in treatment response to atomoxetine and the correlation between health-related quality of life and attention deficit\/hyperactivity disorder core symptoms: meta-analysis of five atomoxetine trials","volume":"4","author":"Wehmeier","year":"2010","journal-title":"Child Adolesc Psychiatry Ment Health"},{"key":"10.1016\/j.jaac.2013.11.005_bib9","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/01.chi.0000190352.90946.0b","article-title":"Do children and adolescents with ADHD respond differently to atomoxetine?","volume":"45","author":"Wilens","year":"2006","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2013.11.005_bib10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00213-006-0565-2","article-title":"Effect of comorbid symptoms of oppositional defiant disorder on responses to atomoxetine in children with ADHD: a meta-analysis of controlled clinical trial data","volume":"190","author":"Biederman","year":"2007","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.jaac.2013.11.005_bib11","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1177\/0009922810368134","article-title":"Post hoc analysis: early changes in ADHD-RS items predict longer term response to atomoxetine in pediatric patients","volume":"49","author":"Block","year":"2010","journal-title":"Clin Pediatr (Phila)"},{"key":"10.1016\/j.jaac.2013.11.005_bib12","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/CHI.0b013e31819c55b2","article-title":"Clinical responses to atomoxetine in attention-deficit\/hyperactivity disorder: the Integrated Data Exploratory Analysis (IDEA) study","volume":"48","author":"Newcorn","year":"2009","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2013.11.005_bib13","first-page":"678","article-title":"Using meta-analysis to compare the efficacy of medications for attention deficit\/hyperactivity disorder in youths","volume":"34","author":"Faraone","year":"2009","journal-title":"P\u00a0T"},{"key":"10.1016\/j.jaac.2013.11.005_bib14","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/00004703-200408000-00006","article-title":"Improvement in health-related quality of life in children with ADHD: an analysis of placebo controlled studies of atomoxetine","volume":"25","author":"Perwien","year":"2004","journal-title":"J\u00a0Dev Behav Pediatr"},{"key":"10.1016\/j.jaac.2013.11.005_bib15","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1469-7610.2008.01960.x","article-title":"Comparison of symptomatic versus functional changes in children and adolescents with ADHD during randomized, double-blind treatment with psychostimulants, atomoxetine, or placebo","volume":"50","author":"Buitelaar","year":"2009","journal-title":"J\u00a0Child Psychol Psychiatry"},{"key":"10.1016\/j.jaac.2013.11.005_bib16","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/JCP.0b013e3181d21763","article-title":"Quality of life and attention-deficit\/hyperactivity disorder core symptoms: a pooled analysis of 5 non-US atomoxetine clinical trials","volume":"30","author":"Escobar","year":"2010","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.jaac.2013.11.005_bib17","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/chi.0b013e31815d88b2","article-title":"Meta-analysis of suicide-related behavior events in patients treated with atomoxetine","volume":"47","author":"Bangs","year":"2008","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2013.11.005_bib18","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.biopsych.2006.05.044","article-title":"Meta-analysis of aggression or hostility events in randomized, controlled clinical trials of atomoxetine for ADHD","volume":"61","author":"Polzer","year":"2007","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.jaac.2013.11.005_bib19","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00213-007-0840-x","article-title":"Efficacy and safety of atomoxetine for attention-deficit\/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis","volume":"194","author":"Cheng","year":"2007","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.jaac.2013.11.005_bib20","series-title":"ADHD Rating Scale\u2013IV: Checklists, Norms, and Clinical Interpretations","author":"DuPaul","year":"1998"},{"key":"10.1016\/j.jaac.2013.11.005_bib21","series-title":"School-Based Assessments and Interventions for ADD","author":"Swanson","year":"1992"},{"key":"10.1016\/j.jaac.2013.11.005_bib22","unstructured":"Yamazaki K, Kimura T, Koishi S, et\u00a0al. Preparation of the ADHD Rating Scale\u2013IV Japanese Version and its discriminative capability. Normative data of ADHD RS-IV: Japanese Version (Preparation of the diagnostic and treatment guideline for ADHD based on empirical research: research for psychiatric and neurological disorders funded by the Ministry of Health and Welfare in 2001) [in Japanese] Kambayashi Y. Chuui kekkan=Tadousei shougai no shindan _ Chiryou gaidorain sakusei to sono jishouteki kenkyuu. Japan Ministry of Health and Welfare, Heisei 11\u201313 nendo kenkyuu houkokusho: 2002;23-35."},{"key":"10.1016\/j.jaac.2013.11.005_bib23","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1089\/10445460050167313","article-title":"Pemoline treatment of adolescents with attention deficit hyperactivity disorder: a short term controlled trial","volume":"10","author":"Bostic","year":"2000","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.jaac.2013.11.005_bib24","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1097\/01.chi.0000163280.47221.c9","article-title":"A\u00a0randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD","volume":"44","author":"Weiss","year":"2005","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2013.11.005_bib25","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1023\/A:1022602400621","article-title":"The revised Conners' Parent Rating Scale (CPRS-R): factor structure, reliability, and criterion validity","volume":"26","author":"Conners","year":"1998","journal-title":"J\u00a0Abnorm Child Psychol"},{"key":"10.1016\/j.jaac.2013.11.005_bib26","series-title":"ECDEU Assessment Manual for Psychopharmacology, Revised","author":"Guy","year":"1976"},{"key":"10.1016\/j.jaac.2013.11.005_bib27","first-page":"839","article-title":"Clinical global impressions","volume":"21","year":"1985","journal-title":"Psychopharmacol Bull"},{"key":"10.1016\/j.jaac.2013.11.005_bib28","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1023\/A:1022606501530","article-title":"Revision and restandardization of the Conners Teacher Rating Scale (CTRS-R): factor structure, reliability, and criterion validity","volume":"26","author":"Conners","year":"1998","journal-title":"J\u00a0Abnorm Child Psychol"},{"key":"10.1016\/j.jaac.2013.11.005_bib29","unstructured":"Eli Lilly and Co. Summary ID# 6477(a): Clinical Study Summary: Study B4Z-US-LYBP (Acute Therapy Phase). Available at: http:\/\/www.lillytrials.com\/results\/Strattera.pdf.p.872-878. Accessed February 6,\u00a02012."},{"key":"10.1016\/j.jaac.2013.11.005_bib30","unstructured":"Sutton VK, Sumner C, Allen A, Feng W, Schuh K, Michelson D. Validity, reliability, and responsiveness of the DPREMB-R Scale for\u00a0ADHD. In: Scientific Proceedings of the 50th Anniversary Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP). Miami Beach, FL, October 14\u201319, 2003, pp.\u00a0169-170."},{"key":"10.1016\/j.jaac.2013.11.005_bib31","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1001\/archpedi.156.4.384","article-title":"Measuring quality of life in children with attention deficit\/hyperactivity disorder and their families: development and evaluation of a new tool","volume":"156","author":"Landgraf","year":"2002","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"Suppl 1","key":"10.1016\/j.jaac.2013.11.005_bib32","article-title":"Validity of the health-related quality of life assessment in the ADORE study: parent report form of the CHIP-CE edition","volume":"15","author":"Riley","year":"2006","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2013.11.005_bib33","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/01.mlr.0000114909.33878.ca","article-title":"The parent report form of the CHIP-Child Edition: reliability and validity","volume":"42","author":"Riley","year":"2004","journal-title":"Med Care"},{"key":"10.1016\/j.jaac.2013.11.005_bib34","doi-asserted-by":"crossref","unstructured":"KINDL: first psychometric and content analytical results. Qual Life Res. 7:399-407.","DOI":"10.1023\/A:1008853819715"},{"key":"10.1016\/j.jaac.2013.11.005_bib35","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s11136-010-9803-5","article-title":"Effect of atomoxetine on quality of life and family burden: results from a randomized, placebo-controlled, double-blind study in children and adolescents with ADHD and comorbid oppositional defiant or conduct disorder","volume":"20","author":"Wehmeier","year":"2011","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jaac.2013.11.005_bib36","unstructured":"Landgraf JM, Abetz L, Ware JE. The CHQ User's Manual, 1st ed. The Health Institute, New England Medical Center, Boston; 1996."},{"key":"10.1016\/j.jaac.2013.11.005_bib37","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control ClinTrials"},{"key":"10.1016\/j.jaac.2013.11.005_bib38","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"Br Med J"},{"key":"10.1016\/j.jaac.2013.11.005_bib39","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"Br Med J"},{"key":"10.1016\/j.jaac.2013.11.005_bib40","doi-asserted-by":"crossref","DOI":"10.1212\/01.wnl.0000188869.58300.a7","article-title":"Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders","volume":"65","author":"Allen","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.jaac.2013.11.005_bib41","unstructured":"Eli Lilly and Co. Summary ID# 4908: Clinical Study Summary: Study B4Z-US-LYAS. Available at: http:\/\/www. lillytrials.com\/results\/Strattera.pdf.p.358-384. Accessed February 6,\u00a02012."},{"key":"10.1016\/j.jaac.2013.11.005_bib42","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1089\/cap.2007.0066","article-title":"Efficacy and safety of atomoxetine in adolescents with attention-deficit\/hyperactivity disorder and major depression","volume":"17","author":"Bangs","year":"2007","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.jaac.2013.11.005_bib43","unstructured":"Eli Lilly and Co. Summary ID# 5004: Clinical Study Summary: Study B4Z-MC-LYAX. Available at: http:\/\/www. lillytrials.com\/results\/Strattera.pdf.p.521-547. Accessed February 6,\u00a02012."},{"key":"10.1016\/j.jaac.2013.11.005_bib44","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2006-1880","article-title":"Atomoxetine for the treatment of attention-deficit\/hyperactivity disorder and oppositional defiant disorder. Atomoxetine ADHD\/ODD Study Group","volume":"121","author":"Bangs","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaac.2013.11.005_bib45","unstructured":"Eli Lilly and Co. Summary ID# 7068: Clinical Study Summary: Study B4Z-MC-LYBX. Available at: http:\/\/www. lillytrials.com\/results\/Strattera.pdf.p.1057-1068. Accessed February 6,\u00a02012."},{"key":"10.1016\/j.jaac.2013.11.005_bib46","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1177\/0009922809335321","article-title":"Once-daily atomoxetine for treating pediatric attention-deficit\/hyperactivity disorder: comparison of morning and evening dosing","volume":"48","author":"Block","year":"2009","journal-title":"Clin Pediatr (Phila)"},{"key":"10.1016\/j.jaac.2013.11.005_bib47","unstructured":"Eli Lilly and Co. Summary ID# 7972: Clinical Study Summary: Study B4Z-US-LYCC. Available at: http:\/\/www. lillytrials.com\/results\/Strattera.pdf.p.1198-1234. Accessed February 6,\u00a02012."},{"key":"10.1016\/j.jaac.2013.11.005_bib48","unstructured":"Eli Lilly and Co. Summary ID# 5003: Clinical Study Summary: Study B4Z-MC-LYAW. Available at: http:\/\/www. lillytrials.com\/results\/Strattera.pdf.p.469-501. Accessed February 6,\u00a02012."},{"key":"10.1016\/j.jaac.2013.11.005_bib49","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1089\/cap.2009.0029","article-title":"Differential effects of atomoxetine on executive functioning and lexical decision in attention-deficit\/hyperactivity disorder and reading disorder","volume":"19","author":"de Jong","year":"2009","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.jaac.2013.11.005_bib50","unstructured":"Eli Lilly and Co. Summary ID# 7955: Clinical Study Summary: Study B4Z-MC-LYCK. Available at: http:\/\/www. lillytrials.com\/results\/Strattera.pdf.p.1182-1197. Accessed February 6,\u00a02012."},{"key":"10.1016\/j.jaac.2013.11.005_bib51","unstructured":"Comparison of Atomoxetine and Placebo in Children With Attention-Deficit\/HyperactivityDisorder (ADHD) and\/or Reading Disorder (RD). Available at: http:\/\/ clinicaltrials.gov\/ct2\/show \/results \/NCT00191906term=LYCK rank=2. Accessed February 6,\u00a02012."},{"key":"10.1016\/j.jaac.2013.11.005_bib52","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.euroneuro.2009.07.008","article-title":"Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit\/hyperactivity disorder and comorbid oppositional defiant disorder: a placebo-controlled Italian study","volume":"19","author":"Dell'Agnello","year":"2009","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.jaac.2013.11.005_bib53","unstructured":"An Italian Study of the Efficacy of Atomoxetine in the Treatment\u00a0of Children and Adolescents With Attention-Deficit\/Hyperactivity Disorder (ADHD) and Comorbid Oppositional Defiant Disorder (ODD). Available at: http:\/\/clinicaltrials.gov \/ct2\/show\/results\/NCT00192023 term=LYCY rank=1. Accessed February 6,\u00a02012."},{"key":"10.1016\/j.jaac.2013.11.005_bib54","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1089\/cap.2009.0111","article-title":"Atomoxetine versus placebo in children and adolescents with attention-deficit\/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany","volume":"21","author":"Dittmann","year":"2011","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.jaac.2013.11.005_bib55","unstructured":"Comparison of Atomoxetine versus Placebo in Children and Adolescents with ADHD and Comorbid ODD in Germany. Available at: http:\/\/clinicaltrials.gov\/ ct2\/show\/results \/NCT00406354term= LYDW rank=1. Accessed February 6,\u00a02012."},{"key":"10.1016\/j.jaac.2013.11.005_bib56","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1089\/cap.2006.0091","article-title":"A\u00a0randomized, double-blind, placebo-controlled clinical trial on once-daily atomoxetine in Taiwanese children and adolescents with attention-deficit\/hyperactivity disorder","volume":"17","author":"Gau","year":"2007","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.jaac.2013.11.005_bib57","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1097\/chi.0b013e3180ca8385","article-title":"Atomoxetine treatment for pediatric patients with attention-deficit\/hyperactivity disorder with comorbid anxiety disorder","volume":"46","author":"Geller","year":"2007","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2013.11.005_bib58","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1542\/peds.114.1.e1","article-title":"Once-daily atomoxetine treatment for children with attention-deficit\/hyperactivity disorder, including an assessment of evening and morning behavior: a\u00a0double-blind, placebo-controlled trial","volume":"114","author":"Kelsey","year":"2004","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaac.2013.11.005_bib59","unstructured":"Eli Lilly and Co. Summary ID# 5670: Clinical Study Summary: Study B4Z-MC-LYBG. Available at: http:\/\/www. lillytrials.com\/results\/Strattera.pdf.p.630-658. Accessed February 6,\u00a02012."},{"key":"10.1016\/j.jaac.2013.11.005_bib60","doi-asserted-by":"crossref","first-page":"e862","DOI":"10.1542\/peds.2010-0825","article-title":"A\u00a0double-blind, placebo-controlled study of atomoxetine in young children with ADHD","volume":"127","author":"Kratochvil","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaac.2013.11.005_bib61","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00787-009-0042-7","article-title":"Atomoxetine in children and adolescents with attention-deficit\/hyperactivity disorder: a 6-week, randomized, placebo-controlled, double-blind trial in Russia","volume":"19","author":"Martenyi","year":"2010","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2013.11.005_bib62","unstructured":"Eli Lilly and Co. Summary ID# 9081: Clinical Study Summary: Study B4Z-MW-LYCZ. Available at: http:\/\/www. lillytrials.com\/results\/Strattera.pdf.p.1461-1472. Accessed February 6,\u00a02012."},{"key":"10.1016\/j.jaac.2013.11.005_bib63","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1176\/appi.ajp.159.11.1896","article-title":"Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study","volume":"159","author":"Michelson","year":"2002","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jaac.2013.11.005_bib64","unstructured":"Eli Lilly and Co. Summary ID# 2746: Clinical Study Summary: Study B4Z-MC-LYAT. Available at: http:\/\/www. lillytrials.com\/results\/Strattera.pdf.p.251-266. Accessed February 6,\u00a02012."},{"key":"10.1016\/j.jaac.2013.11.005_bib65","doi-asserted-by":"crossref","first-page":"E83","DOI":"10.1542\/peds.108.5.e83","article-title":"Atomoxetine in the treatment of children and adolescents with attention-deficit\/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Atomoxetine ADHD Study Group","volume":"108","author":"Michelson","year":"2001","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaac.2013.11.005_bib66","unstructured":"Eli Lilly and Co. Summary ID# 3468: Clinical Study Summary: Study B4Z-MC-LYAC. Available at: http:\/\/www. lillytrials.com\/results\/Strattera.pdf.p.267-289. Accessed February 6,\u00a02012."},{"key":"10.1016\/j.jaac.2013.11.005_bib67","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1185\/03007990903316152","article-title":"Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-na\u00efve children and adolescents with attention deficit\/hyperactivity disorder","volume":"25","author":"Montoya","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jaac.2013.11.005_bib68","unstructured":"Efficacy and Safety of Atomoxetine in Children with Recent Diagnosis of Attention-Deficit\/ Hyperactivity Disorder (ADHD). Available at: http:\/\/clinicaltrials.gov\/ct2\/ show\/NCT00191945term= LYDM rank=1. Accessed February 6,\u00a02012."},{"key":"10.1016\/j.jaac.2013.11.005_bib69","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1176\/appi.ajp.2007.05091676","article-title":"Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Atomoxetine\/Methylphenidate Comparative Study Group","volume":"165","author":"Newcorn","year":"2008","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jaac.2013.11.005_bib70","unstructured":"Eli Lilly and Co. Summary ID# 5831: Clinical Study Summary: Study B4Z-MC-LYBI. Available at: http:\/\/www. lillytrials.com\/results\/Strattera.pdf.p.708-781. Accessed February 6,\u00a02012."},{"key":"10.1016\/j.jaac.2013.11.005_bib71","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/00004583-200503000-00008","article-title":"Atomoxetine treatment in children and adolescents with attention-deficit\/hyperactivity disorder and comorbid oppositional defiant disorder","volume":"44","author":"Newcorn","year":"2005","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2013.11.005_bib72","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.4088\/JCP.v63n1209","article-title":"Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit\/hyperactivity disorder","volume":"63","author":"Spencer","year":"2002","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.jaac.2013.11.005_bib73","unstructured":"Eli Lilly and Co. Summary ID# 1586: Clinical Study Summary: Study B4Z-MC-HFBK. Available at: http:\/\/www. lillytrials.com\/results\/Strattera.pdf.p.36-50. Accessed February 6,\u00a02012."},{"key":"10.1016\/j.jaac.2013.11.005_bib74","unstructured":"Eli Lilly and Co. Summary ID# 1585: Clinical Study Summary: Study B4Z-MC-HFBD. Available at: http:\/\/www. lillytrials.com\/results\/Strattera.pdf.p.22-35. Accessed February 6,\u00a02012."},{"key":"10.1016\/j.jaac.2013.11.005_bib75","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1089\/cap.2006.16.699","article-title":"Placebo-controlled study of the effects of atomoxetine on bladder control in\u00a0children with nocturnal enuresis","volume":"16","author":"Sumner","year":"2006","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.jaac.2013.11.005_bib76","unstructured":"Eli Lilly and Co. Summary ID# 5671: Clinical Study Summary: Study B4Z-US-LYBH. Available at: http:\/\/www. lillytrials.com\/results\/Strattera.pdf.p.659-707. Accessed February 6,\u00a02012."},{"key":"10.1016\/j.jaac.2013.11.005_bib77","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s00787-009-0031-x","article-title":"Atomoxetine improves patient and family coping in attention deficit\/hyperactivity disorder: a randomized, double-blind, placebo-controlled study in Swedish children and adolescents","volume":"18","author":"Svanborg","year":"2009","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2013.11.005_bib78","unstructured":"Eli Lilly and Co. Summary ID# 6671: Clinical Study Summary: Study B4Z-SO-LY15. Available at: http:\/\/www. lillytrials.com\/results\/Strattera.pdf.p.924-951. Accessed February 6,\u00a02012."},{"key":"10.1016\/j.jaac.2013.11.005_bib79","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1089\/cap.2008.0154","article-title":"A\u00a0randomized, double-blind, placebo-controlled study of atomoxetine in Japanese\u00a0children and adolescents with attention-deficit\/hyperactivity disorder","volume":"19","author":"Takahashi","year":"2009","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.jaac.2013.11.005_bib80","unstructured":"Eli Lilly and Co. Summary ID# 5285: Clinical Study Summary: Study B4Z-JE-LYBC. Available at: http:\/\/www. lillytrials.com\/results\/Strattera.pdf.p.560-602. Accessed February 6,\u00a02012."},{"key":"10.1016\/j.jaac.2013.11.005_bib81","first-page":"573","article-title":"Randomized, controlled trial of atomoxetine for attention-deficit\/hyperactivity disorder in adolescents with substance use disorder","volume":"49","author":"Thurstone","year":"2010","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2013.11.005_bib82","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1089\/cap.2010.0142","volume":"21","author":"Wehmeier","year":"2011","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.jaac.2013.11.005_bib83","unstructured":"Comparison of Atomoxetine Versus Placebo in Children With Attention-Deficit\/Hyperactivity Disorder (ADHD). Available at:\u00a0http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00546910term=LYDV rank=1. Accessed February 6,\u00a02012."},{"key":"10.1016\/j.jaac.2013.11.005_bib84","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jaac.2010.10.001","article-title":"Safety and efficacy of ABT-089 in pediatric attention-deficit\/hyperactivity disorder: results from two randomized placebo-controlled clinical trials","volume":"50","author":"Wilens","year":"2011","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2013.11.005_bib85","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.biopsych.2004.08.026","article-title":"The neuropsychopharmacology of attention-deficit\/hyperactivity disorder","volume":"57","author":"Pliszka","year":"2005","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.jaac.2013.11.005_bib86","doi-asserted-by":"crossref","first-page":"e1577","DOI":"10.1542\/peds.2010-1361","article-title":"Treatment of maladaptive aggression in youth: CERT guidelines II. Treatments and ongoing management","volume":"129","author":"Scotto Rosato","year":"2012","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaac.2013.11.005_bib87","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1176\/appi.ajp.2007.05091676","article-title":"Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response","volume":"165","author":"Newcorn","year":"2008","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jaac.2013.11.005_bib88","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1080\/00048670601057767","article-title":"Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial","volume":"41","author":"Wang","year":"2007","journal-title":"Aust N Z J Psychiatry"},{"key":"10.1016\/j.jaac.2013.11.005_bib89","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1097\/chi.0b013e3180335ad1","article-title":"Effect of two different methods of initiating atomoxetine on the adverse event profile of atomoxetine","volume":"46","author":"Greenhill","year":"2007","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2013.11.005_bib90","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1056\/NEJMoa1110212","article-title":"ADHD drugs and serious cardiovascular events in children and young adults","volume":"365","author":"Cooper","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaac.2013.11.005_bib91","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/archgenpsychiatry.2012.647","article-title":"National trends in the office-based treatment of children and adolescents, and adults with antipsychotics","volume":"69","author":"Olfson","year":"2012","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.jaac.2013.11.005_bib92","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s11920-013-0382-3","article-title":"Pharmacoepidemiology of antipsychotic use in youth with ADHD: trends and clinical implications","volume":"15","author":"Birnbaum","year":"2013","journal-title":"Curr Psychiatry Rep"}],"container-title":["Journal of the American Academy of Child & Adolescent Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890856713008149?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890856713008149?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,3]],"date-time":"2019-08-03T22:22:08Z","timestamp":1564870928000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0890856713008149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":92,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S0890856713008149"],"URL":"https:\/\/doi.org\/10.1016\/j.jaac.2013.11.005","relation":{},"ISSN":["0890-8567"],"issn-type":[{"value":"0890-8567","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]}}}